Literature DB >> 20144646

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Justus C Dachsel1, Kenya Nishioka, Carles Vilariño-Güell, Sarah J Lincoln, Alexandra I Soto-Ortolaza, Jennifer Kachergus, Kelly M Hinkle, Michael G Heckman, Barbara Jasinska-Myga, Julie P Taylor, Dennis W Dickson, Rachel A Gibson, Faycal Hentati, Owen A Ross, Matthew J Farrer.   

Abstract

LRRK2 mutations are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism identified to date. A remarkable feature of this form of parkinsonism is the variable penetrance of symptom manifestation resulting in a wide range of age-at-onset in patients. Herein we use a functional approach to identify the Lrrk1 protein as a potential disease modifier demonstrating an interaction and heterodimer formation with Lrrk2. In addition, evaluation of LRRK1 variants in our large Lrrk2 p.G2019S-parkinsonism series from a Tunisian (n=145) identified a missense mutation (p.L416M) resulting in an average 6.2 years younger age at disease onset. In conclusion we show that the interaction of Lrrk1-Lrrk2 can form protein dimers and this interaction may influence the age of symptomatic manifestation in Lrrk2-parkinsonism patients. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20144646      PMCID: PMC2847049          DOI: 10.1016/j.mad.2010.01.009

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  27 in total

1.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

2.  Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data.

Authors:  Bingshan Li; Suzanne M Leal
Journal:  Am J Hum Genet       Date:  2008-08-07       Impact factor: 11.025

3.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

Review 4.  The Roco protein family: a functional perspective.

Authors:  Ignacio Marín; Wouter N van Egmond; Peter J M van Haastert
Journal:  FASEB J       Date:  2008-06-03       Impact factor: 5.191

5.  Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.

Authors:  Saurabh Sen; Philip J Webber; Andrew B West
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

6.  The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.

Authors:  Elisa Greggio; Jean-Marc Taymans; Eugene Yuejun Zhen; John Ryder; Renée Vancraenenbroeck; Alexandra Beilina; Peng Sun; Junpeng Deng; Howard Jaffe; Veerle Baekelandt; Kalpana Merchant; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2009-09-03       Impact factor: 3.575

7.  Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?

Authors:  Frank Gillardon
Journal:  J Neurochem       Date:  2009-06-22       Impact factor: 5.372

8.  Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro.

Authors:  F Gillardon
Journal:  Neuroscience       Date:  2009-06-25       Impact factor: 3.590

9.  Screening of LRRK2 interactants by yeast 2-hybrid analysis.

Authors:  Xiao-ye Zheng; Mei Yang; Jie-qiong Tan; Qian Pan; Zhi-gao Long; He-ping Dai; Kun Xia; Jia-hui Xia; Zhuo-hua Zhang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2008-10

10.  LRRK2 regulates synaptic vesicle endocytosis.

Authors:  Narae Shin; Hyerhan Jeong; Jungsun Kwon; Hye Young Heo; Jung June Kwon; Hye Jin Yun; Cy-Hyun Kim; Baek Soo Han; Youren Tong; Jie Shen; Taku Hatano; Nobutaka Hattori; Kwang-Soo Kim; Sunghoe Chang; Wongi Seol
Journal:  Exp Cell Res       Date:  2008-03-05       Impact factor: 3.905

View more
  9 in total

Review 1.  LRRK2 pathobiology in Parkinson's disease.

Authors:  Ian Martin; Jungwoo Wren Kim; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2014-10-10       Impact factor: 5.372

Review 2.  The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Authors:  Rebekah G Langston; Iakov N Rudenko; Mark R Cookson
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

3.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.

Authors:  Youren Tong; Hiroo Yamaguchi; Emilie Giaime; Scott Boyle; Raphael Kopan; Raymond J Kelleher; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

4.  A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway.

Authors:  Alena Salašová; Chika Yokota; David Potěšil; Zbyněk Zdráhal; Vítězslav Bryja; Ernest Arenas
Journal:  Mol Neurodegener       Date:  2017-07-11       Impact factor: 14.195

Review 5.  Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols.

Authors:  Francis Herman; Susan Westfall; Justin Brathwaite; Giulio M Pasinetti
Journal:  Front Pharmacol       Date:  2018-08-28       Impact factor: 5.810

6.  Comparative and evolutionary analysis of RIP kinases in immune responses.

Authors:  Shangge Lv; Yu Jiang; Yuzheng Li; Ruilin Huang; Lingyu Peng; Zhaoyin Ma; Nan Lu; Xiaoying Lin; Jie Yan
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772

7.  A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease.

Authors:  Patricia Gómez-Suaga; Elena Fdez; Marian Blanca Ramírez; Sabine Hilfiker
Journal:  Parkinsons Dis       Date:  2012-12-03

8.  Rare variants in LRRK1 and Parkinson's disease.

Authors:  Eva C Schulte; Daniel C Ellwanger; Sybille Dihanich; Claudia Manzoni; Katrin Stangl; Barbara Schormair; Elisabeth Graf; Sebastian Eck; Brit Mollenhauer; Dietrich Haubenberger; Walter Pirker; Alexander Zimprich; Thomas Brücke; Peter Lichtner; Annette Peters; Christian Gieger; Claudia Trenkwalder; Hans-Werner Mewes; Thomas Meitinger; Patrick A Lewis; Hans H Klünemann; Juliane Winkelmann
Journal:  Neurogenetics       Date:  2013-11-16       Impact factor: 2.660

9.  Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Authors:  Lauran Reyniers; Maria Grazia Del Giudice; Laura Civiero; Elisa Belluzzi; Evy Lobbestael; Alexandra Beilina; Giorgio Arrigoni; Rita Derua; Etienne Waelkens; Yan Li; Claudia Crosio; Ciro Iaccarino; Mark R Cookson; Veerle Baekelandt; Elisa Greggio; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2014-07-14       Impact factor: 5.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.